Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.048
Neutral
RSI(14)
50.827
Neutral
STOCH(KDJ)(9,3,3)
56.160
Neutral
ATR(14)
0.091
High Vlolatility
CCI(14)
54.788
Neutral
Williams %R
40.678
Buy
TRIX(12,20)
-0.445
Sell
StochRSI(14)
45.773
Sell
Mainz Biomed NV
MYNZ1.170USD
+0.020+1.74%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.79MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Mainz Biomed NV
Currency: USD Updated: 2025-12-24Key Insights
Mainz Biomed NV's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered undervalued, ranking 68/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mainz Biomed NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
14.000
Target Price
+1196.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Mainz Biomed NV Highlights
StrengthsRisks
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 68.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 893.99K.
Overvalued
The company’s latest PE is -0.05, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 386.03K shares, increasing 27.24% quarter-over-quarter.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Mainz Biomed NV is 5.69, ranking 69/78 in the Healthcare Providers & Services industry. Its financial status is stable, and its operating efficiency is low.
Score
Financials
6.25
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.62
Operational Efficiency
2.77
Growth Potential
4.72
Shareholder Returns
7.10
Mainz Biomed NV's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Mainz Biomed NV is 8.02, ranking 19/78 in the Healthcare Providers & Services industry. Its current P/E ratio is -0.05, which is -17.78% below the recent high of -0.04 and -4697.90% above the recent low of -2.51.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 68/78
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24The current earnings forecast score of Mainz Biomed NV is 8.00, ranking 27/78 in the Healthcare Providers & Services industry. The average price target for Mainz Biomed NV is 14.00, with a high of 14.00 and a low of 14.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
14.000
Target Price
+1196.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
65
Total
7
Median
9
Average
Company name
Ratings
Analysts
Mainz Biomed NV
MYNZ
1
CVS Health Corp
CVS
29
HCA Healthcare Inc
HCA
27
Teladoc Health Inc
TDOC
27
Tenet Healthcare Corp
THC
24
Universal Health Services Inc
UHS
22
1
2
3
...
13
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Mainz Biomed NV is 1.36, ranking 76/78 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 1.31 and the support level at 1.01, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.174
Sell
MA10
1.104
Buy
MA20
1.113
Buy
MA50
1.270
Sell
MA100
1.447
Sell
MA200
2.003
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-24Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Mainz Biomed NV is 2.45, ranking 64/78 in the Healthcare Providers & Services industry. The company's beta value is 0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.27
VaR
--
240-Day Maximum Drawdown
+87.81%
240-Day Volatility
+132.28%
Return
Best Daily Return
60 days
+14.95%
120 days
+27.59%
5 years
--
Worst Daily Return
60 days
-11.89%
120 days
-22.22%
5 years
--
Sharpe Ratio
60 days
-0.78
120 days
-0.02
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+87.81%
3 years
+99.66%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.83
3 years
-0.33
5 years
--
Skewness
240 days
+0.46
3 years
+0.76
5 years
--
Volatility
Realised Volatility
240 days
+132.28%
5 years
--
Standardised True Range
240 days
+27.46%
5 years
--
Downside Risk-Adjusted Return
120 days
-3.43%
240 days
-3.43%
Maximum Daily Upside Volatility
60 days
+127.17%
Maximum Daily Downside Volatility
60 days
+69.12%
Liquidity
Average Turnover Rate
60 days
+29.55%
120 days
+33.46%
5 years
--
Turnover Deviation
20 days
-78.68%
60 days
-79.75%
120 days
-77.07%
Peer Comparison
Healthcare Providers & Services
Mainz Biomed NV
MYNZ
5.04 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Chemed Corp
CHE
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lifestance Health Group Inc
LFST
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Natera Inc
NTRA
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Brightspring Health Services Inc
BTSG
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Option Care Health Inc
OPCH
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Mainz Biomed NV?
The TradingKey Stock Score provides a comprehensive assessment of Mainz Biomed NV based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Mainz Biomed NV’s performance and outlook.
How do we generate the financial health score of Mainz Biomed NV?
To generate the financial health score of Mainz Biomed NV, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Mainz Biomed NV's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Mainz Biomed NV.
How do we generate the company valuation score of Mainz Biomed NV?
To generate the company valuation score of Mainz Biomed NV, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Mainz Biomed NV’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Mainz Biomed NV’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Mainz Biomed NV.
How do we generate the earnings forecast score of Mainz Biomed NV?
To calculate the earnings forecast score of Mainz Biomed NV, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Mainz Biomed NV’s future.
How do we generate the price momentum score of Mainz Biomed NV?
When generating the price momentum score for Mainz Biomed NV, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Mainz Biomed NV’s prices. A higher score indicates a more stable short-term price trend for Mainz Biomed NV.
How do we generate the institutional confidence score of Mainz Biomed NV?
To generate the institutional confidence score of Mainz Biomed NV, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Mainz Biomed NV’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Mainz Biomed NV.
How do we generate the risk management score of Mainz Biomed NV?
To assess the risk management score of Mainz Biomed NV, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Mainz Biomed NV’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Mainz Biomed NV.
